1. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL. (23rd June 2022) Authors: Zinzani, P. L.; Özcan, M.; Sapunarova, K.; Jurczak, W.; Hamed, A.; Bouabdallah, K.; Saydam, G.; Geissler, K.; Szomor, Á.; Lazaroiu, M.; Salar, A.; Tempescul, A.; Nalcaci, M.; Gercheva, L.; Egyed, M.; Panayiotidis, P.; Mongay Soler, L.; Cao, A.; Phelps, C.; H Childs, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS. (23rd June 2022) Authors: Geissler, K.; Koristek, Z.; Bernal del Castillo, T.; Novák, J.; Rodriguez Macias, G.; Metzelder, S. K.; Illes, A.; Nagy, A.; Mayer, J.; Arnan, M.; Keating, M.-M.; Krauter, J.; Lunghi, M.; Stefano Fracchiolla, N.; Platzbecker, U.; Santini, V.; Sano, Y.; Oganesian, A.; Keer, H.; Lübbert, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1). (23rd June 2022) Authors: DeZern, A.; Marconi, G.; Deeren, D.; Diez Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonášová, A.; Morozova, E.; Geissler, K.; Ofran, Y.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Hodgson, G.; Madigan, C.; Roth, D. A.; Kelly, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1800 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS. (May 2023) Authors: Dezern, A.; Fenaux, P.; Deeren, D.; Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonasova, A.; Geissler, K.; Ofran, Y.; Klimek, V.; Volkert, A.; Chisholm, J.; Hu, B.; Hodgson, G.; Roth, D.A.; Kelly, M.; Marconi, G. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗